



Dear Geneos stakeholders and well-wishers,

It is with great pleasure that I write to you my annual letter ushering in 2024. We have fully enrolled our GT-30 Phase 1/2 study in advanced hepatocellular cancer (HCC, liver cancer). We look forward to reporting our complete top-line clinical trial data in the coming months at an upcoming scientific conference. The GT-30 clinical trial represents a major milestone for the company demonstrating feasibility of our personalized therapeutic cancer vaccines (PTCV) and the company's ability to broadly operationalize the treatments.

The clinical data to-date is even more remarkable. In October 2023 we reported data from the first 34 patients and showed 8 of 34 patients achieved a complete response or complete molecular response. For one patient we created a path to a complete response as they became a candidate for secondary resection. 3 additional patients on the trial have achieved a partial clinical response. [See [link](#) for more details]

Advanced HCC is one of the most difficult to treat cancers, and is notorious for the extremely rare complete responses observed following treatment. Our study treated patients with their PTCV in combination with the PD1 agent, pembrolizumab. Previous studies with PD1 agents such as pembrolizumab, nivolumab, durvalumab, tislelizumab, avelumab, or sintilimab as single agents, reported a tumor response rate of 12 to 18 percent and a complete response in about two percent of the treated patients. ***In contrast, the GT-30 study is on track to report an overall response rate of greater than 30% and a complete response rate of greater than 8% as detected by MRI scans.***

We are so proud of our very first patient--a patient with a form of brain cancer who first underwent surgery in 2018. She then started treatment in 2019 (still ongoing) with our PTCV as her only treatment for preventing recurrence of cancer. ***She celebrated her 5yr anniversary in 2023*** and remains cancer free.

Driven by the impact we are having on our patients, Geneos had an exciting 2023 where the company was recognized for its innovation by our peers and the media. In 2023, Geneos was:

- Nominated for the 2023 Prix Galien USA Startup Award. It was an honor to be nominated with such a prestigious group of life science innovators
- Profiled as an Emerging Company by Biocentury. [See [link](#) for more details]
- Featured in Precision Medicine Online article for its clinical trial progress. [See [link](#) for more details]
- Selected to present our data at major cancer conferences – AACR, ASCO, Neoantigens Summit

In 2023, we attracted 2 new institutional investors to our company and closed \$10 million of Series A3 financing to fund the company operations through 2024. Geneos continues to operate in a capital efficient manner with a lean and highly experienced, yet nimble, team.

Looking ahead, we expect to finish the GT-30 study in 2024 and complete preparations for a Phase 2 randomized controlled trial in HCC. We sincerely appreciate the support of our investors, partners, advisors, and clinical investigators and their belief in our vision. ***Together we are making a difference with our personalized cancer vaccines - one patient at a time.***

More details on the GT-EPIC™ platform and our programs are at our website: www.geneostx.com

Upwards and onwards to a transformational 2024!

A handwritten signature in black ink that reads "N. Sardesai".

Niranjan Y. Sardesai, Ph.D.

Founder, President & CEO